Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

NCT00084487 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

NIH

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer

Interventions

DRUG: becatecarin

Sponsor

National Cancer Institute (NCI)